Vator Securities advises Gaming Corps on 32 MSEK Capital Raise
Gaming Corps AB is a development company that operates in the global digital gaming market by developing casino games and computer games in two business areas – iGaming and Gaming. The Company was founded in 2014 and has been listed on Nasdaq First North Growth Market since 2015.
The company works mainly with two business models, the first of which consists of the development of non-exclusive games that can be offered to more than one operator. The second business model relates to the development of tailor-made and/or exclusive games for individual operators, as well as various levels of branding and theme customization based on their needs.
Read More
Vator Securities advises Moberg Pharma on 336 MSEK Capital Raise
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries.
MOB-015 is available in Sweden under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada.
Read More
Vator Securities advises Magle Group in Acquisition of pK Biotech ApS and pK Chemicals
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.
pK Chemicals, headquartered in Denmark, is a leading player in the global pharmaceutical and medico sectors. Known for its production of technical Dextran and Dextran Derivatives, pK Chemicals has 65 employees and operates two manufacturing sites in Denmark. In 2023, pK Chemicals reported a gross profit of approximately SEK 116 million, with a profit from operating activities of approximately SEK 17 million.
Read More
Listing of Tingsvalvet Fastighets AB on Nasdaq First North Growth Market
Vator Securities acts as the Listing Agent for Tingsvalvet Fastighets AB during the listing on Nasdaq First North Growth Market.
Tingsvalvet is a cash flow-driven real estate company focused on commercial properties with high yields, particularly in strong local locations in central Sweden. As of March 31, 2024, the property value amounted to approximately 1.9 billion SEK. The company acquires, refines, and develops high-yield commercial properties and owns easy-to-manage properties with strong cash flows and stable tenants. Tingsvalvet has a diversified property portfolio with an average contract length of 7.9 years.
Read More
Vator Securities advises Yabie on 64 MSEK Capital Raise
Yabie is a fast-growing SaaS company that offers products and services that make everyday life easier for business owners. Since 2017, Yabie has developed an ecosystem of user-friendly checkout and payment solutions used by thousands of businesses in Sweden, from the pizzeria on the corner to IKEA.
Through innovation, scalability and a clear product focus, Yabie is gaining market share at a rapid pace. Yabie has developed an ecosystem of services for business customers to make it easier to get paid and drive their business forward. Yabie offers an innovative and mobile checkout and payment solution for a broad target group, from small businesses up to larger international corporate customers such as IKEA.
Read More
Vator Securities advises Immunovia on 70 MSEK Rights Issue
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Read More
Vator Securities advises ExpreS2ion on 60 MSEK Rights Issue
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines.
The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies.
Read More
Vator Securities advises Scandion Oncology on 60 MSEK Rights Issue
Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Read More